DiaMedica Therapeutics (DMAC) Insider Trading & Ownership $6.52 -0.09 (-1.42%) As of 02/21/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DiaMedica Therapeutics (NASDAQ:DMAC) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage7.20%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$3 MNumber OfInsiders Selling(Last 12 Months)0 Get DMAC Insider Trade Alerts Want to know when executives and insiders are buying or selling DiaMedica Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address DMAC Insider Buying and Selling by Quarter DiaMedica Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/28/2024Koch Thomas VonMajor ShareholderBuy1,200,000$2.50$3,000,000.00 (Data available from 1/1/2013 forward) DMAC Insider Trading Activity - Frequently Asked Questions Who is on DiaMedica Therapeutics's Insider Roster? The list of insiders at DiaMedica Therapeutics includes David J Wambeke, Dietrich John Pauls, Koch Thomas Von, Randall Michael Giuffre, and Scott Kellen. Learn more on insiders at DMAC. What percentage of DiaMedica Therapeutics stock is owned by insiders? 7.20% of DiaMedica Therapeutics stock is owned by insiders. Learn more on DMAC's insider holdings. Which DiaMedica Therapeutics insiders have been buying company stock? The following insiders have purchased DMAC shares in the last 24 months: David J Wambeke ($900,003.24), Dietrich John Pauls ($49,997.17), Koch Thomas Von ($7,999,999.20), Randall Michael Giuffre ($254,150.00), and Scott Kellen ($39,100.00). How much insider buying is happening at DiaMedica Therapeutics? Insiders have purchased a total of 3,265,489 DMAC shares in the last 24 months for a total of $9,243,249.61 bought. DiaMedica Therapeutics Key ExecutivesMr. Dietrich John Pauls MBA (Age 53)President, CEO & Director Compensation: $818.61kMr. Scott Kellen CPA (Age 59)CFO & Corporate Secretary Compensation: $485.43kDr. Kirsten L. Gruis M.D. (Age 51)M.S., Independent Consultant Compensation: $449.29kDr. Ambarish Shah Ph.D.Chief Technology OfficerMr. Dominic R. Cundari (Age 73)Chief Commercial Officer Mr. David J. Wambeke (Age 40)Chief Business Officer Dr. Lorianne K. Masuoka M.D. (Age 63)Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies Maravai LifeSciences Insider Trades Enliven Therapeutics Insider Trades Phibro Animal Health Insider Trades Zymeworks Insider Trades AbCellera Biologics Insider Trades Replimune Group Insider Trades Collegium Pharmaceutical Insider Trades Rocket Pharmaceuticals Insider Trades Evolus Insider Trades ArriVent BioPharma Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NASDAQ:DMAC) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
